UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Revenues:
Finance receivable interest income, including fees	$ 10,822	$ 9,498	$ 30,077	$ 30,519
Pharmaceutical development	0	628	2,153	1,711
Other	60	292	536	395
Total revenues	10,882	10,418	32,766	32,625
Costs and expenses:
Provision (benefit) for credit losses	(931)	1,385	(1,635)	10,777
Loss on impairment of intangibles assets	209	0	209	5,771
Loss on disposal of inventory	314	0	314	0
Interest expense	1,179	1,139	3,464	3,514
Pharmaceutical manufacturing, research and development expense	147	585	1,550	1,635
Change in fair value of acquisition-related contingent consideration	0	0	0	(4,900)
Depreciation and amortization expense	2	234	40	1,169
General and administrative expense	3,286	2,993	9,406	8,597
Income from operations	6,676	4,082	19,418	6,062
Other income (expense), net
Unrealized net gains on warrants	2,640	47	2,563	178
Net gain on exercise and cancellation of warrants	0	0	0	444
Loss on sale of assets	0	0	(82)	0
Discontinued operation, gain (loss) on disposal of discontinued operation, net of tax	1,601	0	1,601	0
Net loss on marketable investments	(246)	(6)	(314)	(168)
Realized gain on early payment of finance receivable	0	0	1,729	0
Gain (loss) on revaluation of finance receivables	0	0	(3,727)	2,495
Realized and unrealized foreign currency transaction gains (losses)	25	251	(113)	775
Income before income tax expense	10,696	4,374	21,075	9,786
Income tax expense	1,916	906	4,220	2,170
Net income	$ 8,780	$ 3,468	$ 16,855	$ 7,616
Net income per share
Basic (in dollars per share)	$ 0.72	$ 0.28	$ 1.38	$ 0.61
Diluted (in dollars per share)	$ 0.72	$ 0.28	$ 1.38	$ 0.61
Weighted average shares outstanding
Basic (in shares)	12,117,000	12,318,000	12,184,000	12,417,000
Diluted (in shares)	12,117,000	12,408,000	12,184,000	12,492,000